RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

The emergence of CRISPR-Cas systems has accelerated the development of gene editing
technologies, which are widely used in the life sciences. To improve the performance of …

Conventional genome engineering with CRISPR–Cas9 creates double-strand breaks
(DSBs) that lead to undesirable byproducts and reduce product purity. Here we report an …

CRISPR–Cas13 systems have recently been used for targeted RNA degradation in various
organisms. However, collateral degradation of bystander RNAs has limited their in vivo …

Summary The type III-E CRISPR-Cas effector Cas7-11, with dual RNase activities for
precursor CRISPR RNA (pre-crRNA) processing and crRNA-guided target RNA cleavage, is …

In prokaryotes, CRISPR-Cas systems provide adaptive immune responses against foreign
genetic elements through RNA-guided nuclease activity. Recently, additional genes with …

The isomerization of xylose to xylulose is considered the most promising approach to initiate
xylose bioconversion. Here, phylogeny-guided big data mining, rational modification, and …

CRISPR/Cas13 effectors have garnered increasing attention as easily customizable tools for
detecting and depleting RNAs of interest. Near perfect complementarity between a target …

Robust and precise transcript targeting in mammalian cells remains a difficult challenge
using existing approaches due to inefficiency, imprecision and subcellular …

The CRISPR-Cas type III-E RNA-targeting effector complex gRAMP/Cas7-11 is associated
with a caspase-like protein (TPR-CHAT/Csx29) to form Craspase (CRISPR-guided …